The addition of cyclin-dependent kinase (CDK) 4/6 inhibitors to endocrine therapy (ET) has improved the outcomes of patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer [6,7]. Here, NR4A1 is linked to breast carcinoma.